Stock Markets May 7, 2026 09:53 AM

Knox Lane to Buy Cross Country Healthcare in $437M All-Cash Deal; Shares Jump 29%

Acquirer will take the workforce solutions firm private at $13.25 per share; closing targeted for Q3 2026 pending approvals

By Jordan Park CCRN

Cross Country Healthcare said it has agreed to be acquired by growth-oriented investment firm Knox Lane in an all-cash transaction that values the company at $437 million. The deal, which pays $13.25 per share, prompted a 29% jump in the company's stock on Thursday and would result in Cross Country Healthcare becoming a privately held platform in Knox Lane’s portfolio if completed in the third quarter of 2026.

Knox Lane to Buy Cross Country Healthcare in $437M All-Cash Deal; Shares Jump 29%
CCRN

Key Points

  • Knox Lane will acquire all outstanding shares of Cross Country Healthcare for $13.25 per share, valuing the deal at $437 million.
  • The offer implies a premium of about 31% to Cross Country Healthcare’s May 6, 2026 closing price and 45% to the 90-day VWAP ending May 6, 2026; the announcement drove a 29% intraday rise in the stock.
  • If completed, Cross Country Healthcare will be taken private, remain operating under its existing name, and become a platform company within Knox Lane’s portfolio, affecting healthcare staffing markets and Nasdaq-listed investors.

Shares of Cross Country Healthcare Inc (NASDAQ:CCRN) climbed 29% on Thursday after the company disclosed a definitive agreement to be acquired by Knox Lane, a growth-oriented investment firm, in an all-cash transaction.

Under the terms of the agreement, Knox Lane will buy every outstanding share of Cross Country Healthcare common stock for $13.25 per share, valuing the transaction at $437 million. The purchase price represents roughly a 31% premium to Cross Country Healthcare’s May 6, 2026 closing price, and a 45% premium to the company’s volume-weighted average trading price for the 90-day period that ended May 6, 2026.

Following the closing of the transaction, Cross Country Healthcare will be taken private and will no longer trade on the Nasdaq exchange. The company is expected to continue operating under the Cross Country Healthcare name and brand as a privately held platform company within Knox Lane’s portfolio.

Kevin Clark, Co-Founder, Chairman and Chief Executive Officer of Cross Country Healthcare, said: "We are excited to be working with Knox Lane, who brings significant and direct expertise in our sector to help Cross Country Healthcare enter its next phase of growth, while delivering significant and immediate value to our stockholders."

John Bailey, Managing Partner at Knox Lane, and Shamik Patel, Partner at Knox Lane, commented that Cross Country Healthcare is "a longstanding leader and innovator in healthcare workforce solutions, with an unparalleled focus on delivering clinical excellence."

The companies indicated the proposed transaction is expected to close in the third quarter of 2026, subject to customary closing conditions. Those conditions include approval by Cross Country Healthcare stockholders and the receipt of all required regulatory approvals.

BofA Securities, Inc. is serving as exclusive financial advisor to Cross Country Healthcare. Davis Polk & Wardwell LLP is acting as legal counsel to the company.


This announcement directly affects market participants in the healthcare staffing and workforce solutions sectors, as well as investors in the company’s Nasdaq-listed equity. It also has relevance to private equity and growth-oriented investment firm activity within healthcare services, given the intention to operate Cross Country Healthcare as a platform company under Knox Lane ownership.

For market observers, the pricing of the deal and the premiums being paid relative to recent trading levels will be key metrics when evaluating the transaction. The timetable hinges on the receipt of stockholder consent and regulatory approvals, and the transaction remains subject to the usual closing conditions for an acquisition of this nature.

Risks

  • The transaction is conditioned on stockholder approval; Cross Country Healthcare investors may or may not approve the deal, which introduces uncertainty for shareholders and market participants.
  • Regulatory approvals are required before closing; any delay or denial could push back the expected third-quarter 2026 completion or prevent the deal from closing, affecting companies and investors tied to the healthcare staffing sector.
  • The deal is subject to customary closing conditions; failure to satisfy these conditions could result in the agreement being terminated, with implications for the company’s capital markets status and private equity plans.

More from Stock Markets

Warby Parker Shares Jump After Q1 Beat and AI Eyewear Reveal May 7, 2026 Tapestry Shares Reverse Course After Stellar Quarter, Fall Sharply in Morning Trade May 7, 2026 W.W. Grainger Posts a Large Q1 Beat, Propelling Shares to New Highs May 7, 2026 Baltic Dry Index Hits Five-Month Peak on Strength in Capesize and Panamax Rates May 7, 2026 PTC Shares Jump After Powerful Q2 Report, Guidance Raise and Large Buyback Plan May 7, 2026